Sintilimab combined with XELOX

Phase 2Biologic

TThe First Affiliated Hospital of Anhui Medical University

Sintilimab combined with XELOX is one of 14 biologic programs targeting Rectal Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rectal AdenocarcinomaActive, not recruiting

Rectal AdenocarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Rectal Adenocarcinoma

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

3 2

Tuoyi

CCoherus Oncology, Inc.

Phase 3

2 3

Erbitux

IImclone

Phase 3

2 4

Eloxatin

Teva

Phase 2

5 5

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

8 6

PD-1 Monoclonal Antibody

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

3 7

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2

1 8

Flagyl

DDePuy Orthopaedics

Phase 2

1 9

Adrucil

EElorac, Inc.

Phase 2

1 10

Wellcovorin

EEastern Cooperative Oncology Group

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Active, not recruiting

Rectal Adenocarcinoma

NCT07127497

Clinical

Trials by Indication[1]

Rectal Adenocarcinoma1 trial

Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma

Active, not recruiting·TThe First Affiliated Hospital of Anhui Medical University·Phase 2·NCT07127497·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sintilimab combined with XELOX. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sintilimab combined with XELOX compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sintilimab combined with XELOX. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital of Anhui Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: TThe First Affiliated Hospital of Anhui Medical University

Sintilimab combined with XELOX

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Rectal Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News